Compare Ascendis Pharma A/S (ASND) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs ProShares UltraPro QQQ ETF — how do they compare? Ascendis Pharma A/S trades at $264.94 (market cap $17.74B), while ProShares UltraPro QQQ ETF trades at $72.57. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ASND | TQQQ | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $87.22 |
52-Week Low | $163.32 | $37.89 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TQQQ (ProShares UltraPro QQQ) trades at $77.03, up 0.9% with a bullish technical signal from moving averages. The leveraged ETF amplifies Nasdaq-100 returns by 3x daily, showing strong historical performance but significant volatility risks. Recent news highlights concerns about leveraged ETFs amplifying market volatility while acknowledging their potential for substantial gains during bull markets.
The outlook remains tied to Nasdaq-100 performance with opportunities for amplified returns in trending markets, but structural costs and volatility decay pose significant risks during market downturns. Investors face asymmetric risk-reward dynamics requiring careful position sizing and risk management strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
